It is a prime concern of Evotec that all relevant target groups receive the same information at the same time. This implies communicating in both English and German.

Please find below the most recent corporate news, ad hoc releases and other announcements of our Company.


Corporate news

Evotec and Chinook Therapeutics enter into strategic collaboration to discover and develop novel precision medicines for chronic kidney diseases
Hamburg, Germany, March 1, 2021

Evotec SE and Chinook Therapeutics, Inc. today announced a strategic collaboration focused on the discovery and development of novel precision medicine therapies for patients with chronic kidney diseases (“CKD”). Based on Evotec’s proprietary comprehensive molecular datasets from thousands of patients across chronic kidney diseases of multiple underlying etiologies, Chinook and Evotec will jointly identify, characterise and validate novel mechanisms and discover and develop precision medicines. 

Evotec and Related Sciences enter integrated drug discovery and development partnership
Hamburg, Germany, February 9, 2021

Evotec SE announced today that the Company has entered into an integrated multi-target drug discovery agreement with biotech venture creation firm Related Sciences to generate multiple drug development candidates, biomarkers, and IND filings over a multi-year period.

Evotec and Medical Center Hamburg-Eppendorf Enter Partnership to Develop iPSC-Based Tissue Therapy for Heart Failure
Hamburg, Germany, February 4, 2021

Evotec SE today announced that the Company has entered into a multi-year partnership with the Medical Center Hamburg-Eppendorf (“UKE”) for the development of a highly innovative first-in-class cell therapy approach for the treatment of heart failure.

Evotec Statement on COVID-19
Hamburg, Germany, February 1, 2021

Many of you have been asking us about the Coronavirus and its potential impact on Evotec and its affiliates. At Evotec, we are actively managing our operations to maintain business continuity while taking measures to protect the health and wellbeing of our employees, their families and the local communities in which they live and work. We have taken a number of steps to ensure the continued health and safety of our colleagues and prepare our business during this challenging time.

Evotec CSO Cord Dohrmann Appointed to German Council of Science and Humanities
Hamburg, Germany, February 1, 2021

Evotec today announced that Dr Cord Dohrmann has been appointed to the German Council of Science and Humanities (German: “Wissenschaftsrat”) for a term of three years. He is appointed by the Federal President Frank-Walter Steinmeier on the joint recommendation of the German Federal Government and the governments of the German states.

Evotec Starts Clinical Development of Chikungunya Antibody together with NIAID and Leading Academic Research Organisation
Hamburg, Germany, January 28, 2021

Evotec SE today announced that EVT894, a monoclonal antibody to treat and potentially prevent chikungunya virus infections, has entered clinical development. 

Just – Evotec Biologics Expands Contract with the Department of Defense for Manufacturing of Monoclonal Antibodies
Hamburg, Germany, January 27, 2021

Evotec SE today announced that the U.S. Department of Defense (“DOD”) awarded its Seattle, Washington-based subsidiary, Just – Evotec Biologics, Inc., an agreement worth $28.6 million for the production of monoclonal antibodies (“mAbs”) for use in the development of a treatment and/or prophylaxis for COVID-19.

Evotec to attend upcoming investor conferences
Hamburg, Germany, January 7, 2021

Evotec SE announced today that its management will be presenting at and attending the following upcoming conferences in the first quarter of 2021:

Evotec achieves milestone in its neurodegeneration collaboration with Bristol Myers Squibb
Hamburg, Germany, January 5, 2021

Evotec SE announced today that the Company has received a US$ 6 m payment from Bristol Myers Squibb Company (NYSE:BMY) within the companies’ iPSC-based neuroscience partnership. The payment follows Bristol Myers Squibb’s decision to add another drug discovery project to the partnership’s portfolio.


Ad hoc releases

Please find below Evotec's most recent ad hoc releases according to Article 17 European Market Abuse Regulation (MAR).



Other announcements


The following annoucement has been published in the German Federal Gazette in accordance with the German Conversion Act (Umwandlungsgesetz) in 2013. Pursuant to the German Conversion Act, certain transaction intended by Evotec SE, e.g. up-stream mergers, have to be announced in the Federal Gazette (Bundesanzeiger).

Contact us

Gabriele Hansen

SVP, Head of Global Corporate Communications & Marketing

T +49 40 560 81 255 F +49 40 560 81 333 vCard

Volker Braun

SVP, Head of Global Investor Relations & ESG

T +49 40 560 81 775 F +49 40 560 81 333 vCard

Hinnerk Rohwedder

Senior Specialist Corporate Communications

T +49 40 560 81 281 F +49 40 560 81 222 vCard

Anja Ben Lekhal

Investor Relations Associate

T + 49 40 56081 210 F +49 40 56081 222 vCard